Use of EP4 receptor antagonists in the treatment of cartilage disease
This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a pharmaceutical composition for the treatment of cartilage disease which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of cartilage disease in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.
1. A method for inhibiting cartilage destruction to treat osteoarthritis, which comprises administering to a human or animal in need thereof a therapeutically effective amount of 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid or the pharmaceutically acceptable salt thereof normalizes a condition of a cartilage lesion by at least one effect selected from the group consisting of a chondroprotective effect, a cartilage destruction suppressing effect and an anti-catabolic effect on cartilage.
3. The method of claim 1 , which further comprises administering a therapeutically effective amount of one or more additional compounds known to be useful in the treatment or prevention of a cartilage disease or a symptom thereof.
4. The method of claim 3 , wherein the one or more additional compounds known to be useful in the treatment or prevention of the cartilage disease or the symptom thereof is selected from the group consisting of an NSAID, a COX-2 inhibitor, a steroid, a matrix metalloproteinase inhibitor and hyaluronic acid.
5. A method for normalizing a condition of a cartilage lesion by inhibiting a cartilage destruction to treat osteoarthritis, which comprises administering to a human or animal in need thereof a therapeutically effective amount of 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , which further comprises administering a therapeutically effective amount of one or more additional compounds known to be useful in the treatment or prevention of a cartilage disease or a symptom thereof.
7. The method of claim 6 , wherein the one or more additional compounds known to be useful in the treatment or prevention of the cartilage disease or the symptom thereof is selected from the group consisting of an NSAID, a COX-2 inhibitor, a steroid, a matrix metalloproteinase inhibitor and hyaluronic acid.